Regenerative Medical Technology (RMTG) EBT Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted EBT Margin of 41.46% for Q2 2026, up 44.19% on a QoQ basis from 74.29% in Q1 2026, and up 9130.0% year-over-year from 0.45% in Q2 2025.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) EBT Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology has reported EBT Margin for 9 years, with the latest figure at 41.46% in Q2 2026.
- On a quarterly basis, EBT Margin rose 9130.0% year-over-year to 41.46% in Q2 2026; TTM through Jun 2026 was 104.93%, a 3081.0% decrease from a year earlier, with the FY2025 full-year figure at 163.03%, down 2766.0% from the prior year.
- EBT Margin was 41.46% for Q2 2026 at Regenerative Medical Technology, up from 74.29% in the prior quarter.
- The five-year high for EBT Margin was 9.44% in Q1 2023, with the low at 563.32% in Q1 2022.
- Average EBT Margin over 5 years is 220.47%, with a median of 193.52% recorded in 2025.
- The sharpest annual moves came in 2022 and 2025: EBT Margin surged 1006704 bps in 2022, then sank 24365 bps in 2025.
- Over 5 years, EBT Margin stood at 433.93% in 2022, then soared by 34 bps to 287.25% in 2023, then jumped by 85 bps to 42.3% in 2024, then tumbled by 248 bps to 147.2% in 2025, then soared by 72 bps to 41.46% in 2026.
- The last three EBT Margin figures came in at 41.46% (Q2 2026), 74.29% (Q1 2026), and 147.2% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.22 Bn | 9.37 Bn | 112.79 Mn | 55.43% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | -885.91% |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn | -49.02% |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | 14.32% |
| 5 | uniQure | 3.01 Bn | 3.01 Bn | 5.49 Mn | -1,356.24% |
| 6 | Beam Therapeutics | 2.54 Bn | 2.54 Bn | - | -24,299.18% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | -0.44% |
| 9 | Vericel | 1.95 Bn | 1.78 Bn | 56.40 Mn | 2.88% |
| 10 | Regenerative Medical Technology | 1.18 Mn | -139,694.93 | 2.58 Mn | -41.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.46% |
| Mar 31, 2026 | -74.29% |
| Dec 31, 2025 | -147.20% |
| Sep 30, 2025 | -333.47% |
| Jun 30, 2025 | -132.76% |
| Mar 31, 2025 | -55.77% |
| Dec 31, 2024 | -42.30% |
| Sep 30, 2024 | -89.82% |
| Jun 30, 2024 | -261.67% |
| Mar 31, 2024 | -239.83% |
| Dec 31, 2023 | -287.25% |
| Sep 30, 2023 | -267.87% |
| Jun 30, 2023 | -119.23% |
| Mar 31, 2023 | -9.44% |
| Dec 31, 2022 | -433.93% |
| Sep 30, 2022 | -365.74% |
| Jun 30, 2022 | -503.09% |
| Mar 31, 2022 | -563.32% |
| Dec 31, 2021 | -617.97% |
| Sep 30, 2021 | -6,007.83% |